6 and/or UCT<12, then continued treatment is advised, dependent on physician judgement and patient expectations. In treatment responders, omalizumab treatment can be resumed at a later stage after discontinuation with the same degree of symptom control."/> 6 and/or UCT<12, then continued treatment is advised, dependent on physician judgement and patient expectations. In treatment responders, omalizumab treatment can be resumed at a later stage after discontinuation with the same degree of symptom control."/>
article

Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria

Marta Ferrer, Isabelle Boccon-Gibod, Margarida Gonçalo, Hüseyin Serhat İnalöz, André Knulst and 7 more (2017) EUROPEAN JOURNAL OF DERMATOLOGY

Reference details